7093 Atherogenic Index of Plasma Is Strongly Correlated With Cardiovascular Disease Independent of LDL level in the US Population

Abstract Disclosure: H. Ayesh: None. K.D. Niswender: None. B.G. Carranza Leon: None. Introduction: Cardiovascular disease (CVD) poses a global health challenge, prompting exploration of risk factors. The Atherogenic Index of Plasma (AIP), calculated as the readily available TG/HDL-C ratio, stands out as a promising avenue for investigation. Previous studies have reported an independent association between AIP and cardiovascular disease across diverse populations. Despite this recognized significance, there exists a gap in understanding its relevance in the US. This research aims to bridge this gap by examining the AIP-CVD relationship within the US population, utilizing data from the National Health and Nutrition Examination Survey (NHANES). Methods: The study included 4,784 NHANES subjects, with AIP values calculated using the established formula. The outcome was assessed using a combined variable (stroke, myocardial infarction, and CAD). Statistical analysis employed logistic regression to evaluate the AIP-CVD relationship, controlling for age, BMI, hemoglobin A1c, blood pressure, smoking, and LDL levels. Results/Discussion: We observed a significant correlation between AIP and CVD (odds ratio: 1.77, P = 0.026, 95% CI: 1.07-2.94), which persisted after controlling for common risk factors, including HbA1c, BMI, blood pressure, smoking, and LDL levels. Importantly, our findings highlighted the independence of this association from LDL levels—a pivotal observation with implications for healthcare strategies. Our study suggests that even with optimized LDL levels, AIP maintains an independent association with CVD. Existing literature supports the notion that AIP levels are strongly correlated with small dense LDL and remnant cholesterol levels. The pragmatic utility of AIP as a cardiovascular risk marker is evident due to the impracticality and costliness of testing for small dense LDL and remnant cholesterol. Given AIP is based on routine lipid profiles, our data underscores the potential integration of AIP into clinical practice, streamlining risk assessment. As we delve into our findings, the optimization of cardiovascular risk beyond LDL levels emerges as a tangible goal, with AIP emerging as a valuable tool. Larger studies are needed to validate and generalize these findings in the US population. Presentation: 6/2/2024